PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

Michael E. Stokes(FuelCell Energy (United States)), David Surguladze(Intellicell Biosciences (United States)), Nupur Ballal(Intellicell Biosciences (United States)), Nandita Bose(FuelCell Energy (United States)), Leyi Shen(Intellicell Biosciences (United States)), Sharon Huang(Intellicell Biosciences (United States)), Verónica Calvo(Intellicell Biosciences (United States)), Matthew J. Betzenhauser(Buffalo BioLabs), Sho Fujisawa(New York University), Mark J. Mulvihill(FuelCell Energy (United States)), Jennifer Gasparek(Buffalo BioLabs), Alan C. Rigby(FuelCell Energy (United States)), Kirk A. Staschke(Indiana University Health), Eric S. Lightcap, S. Taylor(Pharmaron (United Kingdom)), Crissy Dudgeon(Rutgers, The State University of New Jersey)
Clinical Cancer Research
September 21, 2023
Cited by 27


Related Papers